3Malet Martjno M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,UFT,S-1).A review[J].Oncologist,2002 ; 7(4):288-323.
5Yumine K,Kawahara M.Phase Ⅱ study of S-1,a novel oral fluorouracil.in advanced non-small-cell lung cancer[J].Gan To Kagaku Ryoho,2006;33(1):189.
6Totani Y,Saito Y,Hayashi M,et al.A phase Ⅱ study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer[J].Cancer Chemother Pharmacol Lung Cancer,2009 ;64 (6):1181.
7Kubota K,Sakai H,Yamamoto N,et al.A multi-institution phase Ⅱ / Ⅲ trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small-cell lung cancer[J].J Thorac Oncol,2010 ;5 (5):702.
8Ono A,Naito T,Murakami H,et al.Evaluation of S-1 as third-or further-line chemotherapy in advanced non-small-cell lung cancer[J].Int J Clin Oncol,2010;15 (3):161.
二级参考文献14
1Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5 - fluorouracil (capecitabine, UFT, S-1): A review. Oncologist, 2002; 7 (4): 288 -323
2Hoff PM. the tegafur - based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin and S- 1: A review of their clinical development and therapeutic potential, Invest New Drugs, 2000; 18 (4) : 331 - 342
4Hirata K, Horikoshi N, Aiba K, et at. Pharmacokinetic study of S - 1, a novel oval fluorouracil antitumor drug. Clin Cancer Res, 1999; 5 (8) : 2000- 2005
5Aventis - Sanofi Group. S - 1 oral antlcancer agent improves patients' survival in adjuvant gastric cancer trial versus surgery alone (Press releases)o http:// en. sanofi-aventis.com/press/ppc-15653.asp (January 19, 2007)
6Maehara Y. S - 1 in gastric cancer: A comprehensive review. Gastric Cancer, 2003; 6 (Suppl 1) : 2- 8
7Nagashima F, Ohtsu A, Yoshida S, et al. Japanese nationwide post - marketing survey of S - 1 in patients with advanced gastric cancer. Gastric Cancer, 2005; 8 (1): 6-11
8Aventis - Sanofi Group. S - 1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S - 1 alone (Press releases) . http:// en. sanofi - aventis.com/press/ppc-16728.asp (June 3, 2007)
9Ohtsu A, Baba H, Sakata Y, et al. Phase Ⅱ study of S - 1, a novel oral fluoro- phyrimidine derivative, in patients with metastatic cotorectal carcinoma. Br J Cancer, 2(XX); 83 (2) : 141-145
10Jeung HC, Rha SY, Cho BC. et al. A phase Ⅱ trial of S - 1 monotherapy in metastatic cotorectal cancer after failure of irinotecan - and oxaliplatin - containing regimens. Br J Cancer, 2006; 95 (12): 1637-1641
4Jan Nyrop Jakobsen,Eric Santoni-Rugiu,Jens Benn S?rensen.Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer[J].Journal of Cancer Research and Clinical Oncology.2014(4)
5Simona Carnio,Silvia Novello,Teresa Mele,Matteo Giaj Levra,Giorgio Vittorio Scagliotti.Extending Survival of Stage IV Non Small Cell Lung Cancer[J].Seminars in Oncology.2013
6Masayuki Takeda,Takehiko Kobayashi,Satoshi Marumo,Yoshihiko Koshimo,Takashi Teranishi,Yuichi Higami,Motokazu Kato.Acute cerebral arterial embolism following pemetrexed and carboplatintreatment in non?small?cell lung cancer: A case report[J].Molecular and Clinical Oncology.2013(5)
7Barlesi F, Spano JP, Cortot AB, et al. Systemic treatment of brain metastases from lung cancer[J]. Cancer Radiother, 2015,19(1):43- 47.
8Baykara M, Kurt G, Buyukberber S, et al. Management of brain metastases from non-small cell lung cancer[J]. J Cancer Res Ther, 2014,10(4):915-921.
9Wada M, Yamamoto M, Ryuge S, et al. Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer[J]. Cancer Chemother Pharmacol,2012, 69(4):1005-1011.
10Tomita Y, Oguri T, Takakuwa O, et al. S-1 monotherapy for previously treated non-small cell lung cancer: a retrospective analysis by age and histopathological type [J]. Oncol Lett,2012,3 (2):405-410.
